KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Account Payables: 2009-2024

Historic Change in Account Payables for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to -$1.4 million.

  • Acadia Pharmaceuticals' Change in Account Payables rose 305.99% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 60.63%. This contributed to the annual value of -$1.4 million for FY2024, which is 128.16% down from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Change in Account Payables of -$1.4 million as of FY2024, which was down 128.16% from $4.8 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Change in Account Payables ranged from a high of $5.9 million in FY2022 and a low of -$1.6 million during FY2021.
  • Its 3-year average for Change in Account Payables is $3.1 million, with a median of $4.8 million in 2023.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Change in Account Payables plummeted by 227.22% in 2021 and then skyrocketed by 463.02% in 2022.
  • Yearly analysis of 5 years shows Acadia Pharmaceuticals' Change in Account Payables stood at $1.3 million in 2020, then slumped by 227.22% to -$1.6 million in 2021, then soared by 463.02% to $5.9 million in 2022, then dropped by 18.28% to $4.8 million in 2023, then tumbled by 128.16% to -$1.4 million in 2024.